# Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL

> **NCT04899453** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Primary Vitreoretinal Lymphoma

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Rituximab
- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT04899453
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2022-08-01
- **Final completion:** 2024-08-01
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2021-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04899453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04899453, "Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04899453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*